Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine
2. 2',3'-dideoxy-2',3'-didehydro-beta-d-5-fluorocytidine
3. 2',3'-dideoxy-2',3'-didehydro-beta-l-5-fluorocytidine
4. 2(1h)-pyrimidinone, 4-amino-1-((2s,5r)-2,5-dihydro-5-(hydroxymethyl)-2-furanyl)-5-fluoro-
5. 4-amino-5-fluoro-1-((2s,5r)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)pyrimidin-2(1h)-one
6. Ach-126-443
7. Beta-d-d4fc
8. Beta-l-fd4c
9. D-d4fc
10. Dexelvucitabine
11. Dpc 817
12. Dpc-817
13. Dpc817
14. Incb-8721
15. L-d4fc
16. Reverset
1. 181785-84-2
2. Beta-l-fd4c
3. L-fd4c
4. .beta.-l-fd4c
5. Ach-126,443
6. L-f-d4c
7. Ach-126443
8. L-d4fc
9. 4-amino-5-fluoro-1-((2s,5r)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)pyrimidin-2(1h)-one
10. 4-amino-5-fluoro-1-[(2s,5r)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one
11. M09buf90c0
12. 2(1h)-pyrimidinone, 4-amino-1-((2s,5r)-2,5-dihydro-5-(hydroxymethyl)-2-furanyl)-5-fluoro-
13. 2(1h)-pyrimidinone, 4-amino-1-[(2s,5r)-2,5-dihydro-5-(hydroxymethyl)-2-furanyl]-5-fluoro-
14. Elvucitabine [usan]
15. Elvucitabine [usan:inn]
16. Unii-m09buf90c0
17. Ach 126443
18. Ach 126,443
19. B-l-fd4c
20. Elvucitabine (usan/inn)
21. Elvucitabine [inn]
22. Chembl38700
23. (-)fd4c
24. Schembl1649928
25. Zinc7048
26. Beta-l-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine
27. Dtxsid20171185
28. Bdbm50421604
29. Db06236
30. Hy-117582
31. Cs-0066557
32. A14435
33. D03981
34. J-011630
35. Q1334337
36. .beta.-l-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine
37. 2(1h)-pyrimidinone, 4-amino-1-(2,5-dihydro-5-(hydroxymethyl)-2-furanyl)-5-fluoro-, (2s-cis)-
| Molecular Weight | 227.19 g/mol |
|---|---|
| Molecular Formula | C9H10FN3O3 |
| XLogP3 | -1.3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 2 |
| Exact Mass | 227.07061935 g/mol |
| Monoisotopic Mass | 227.07061935 g/mol |
| Topological Polar Surface Area | 88.2 Ų |
| Heavy Atom Count | 16 |
| Formal Charge | 0 |
| Complexity | 405 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in hepatitis (viral, B) and HIV infection.
Reverse Transcriptase Inhibitors
Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)
Anti-HIV Agents
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)
Elvucitabine is a L-cytosine Nucleoside analog Reverse Transcriptase Inhibitor (NRTIs) anti-HIV drug. NRTI's inhibit the activity of viral RNA-directed DNA polymerase (i.e., reverse transcriptase). It is believed that inhibition of reverse transcriptase interferes with the generation of DNA copies of viral RNA, which, in turn, are necessary for synthesis of new virions. Intracellular enzymes subsequently eliminate the HIV particle that previously had been uncoated, and left unprotected, during entry into the host cell. Thus, reverse transcriptase inhibitors are virustatic and do not eliminate HIV from the body.
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
A Elvucitabine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Elvucitabine, including repackagers and relabelers. The FDA regulates Elvucitabine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Elvucitabine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Elvucitabine supplier is an individual or a company that provides Elvucitabine active pharmaceutical ingredient (API) or Elvucitabine finished formulations upon request. The Elvucitabine suppliers may include Elvucitabine API manufacturers, exporters, distributors and traders.
Elvucitabine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Elvucitabine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Elvucitabine GMP manufacturer or Elvucitabine GMP API supplier for your needs.
A Elvucitabine CoA (Certificate of Analysis) is a formal document that attests to Elvucitabine's compliance with Elvucitabine specifications and serves as a tool for batch-level quality control.
Elvucitabine CoA mostly includes findings from lab analyses of a specific batch. For each Elvucitabine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Elvucitabine may be tested according to a variety of international standards, such as European Pharmacopoeia (Elvucitabine EP), Elvucitabine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Elvucitabine USP).
LOOKING FOR A SUPPLIER?
